98 results about "Adjuvant chemotherapy" patented technology

A system for surgical planning and therapeutic monitoring utilizes imaging data and computer-aided detection (CAD) technology to identify cancerous tumors. A pre-treatment report identifies all volumes of interest (VOIs) and provides data regarding the size and location of each VOI as well as volumetric data for use in surgical planning. The system can be used to monitor the progress of adjuvant chemotherapy or other non-surgical treatment and measures changes in tumor size and location. Post-treatment reports provide data regarding changes in tumor size and location as well as trend data to provide guidance to the physician.

The invention discloses application of active ingredients of juncus effuses in the preparation of medicaments for resisting tumors or inhibiting angiogenesis, health-care food or cosmetics. In the invention, the active ingredients of juncus effuses has the activity of inhibiting the tumors and tumor angiogenesis, and the prepared medicaments for inhibiting the tumors and the tumor angiogenesis can be used for treating or preventing malignancy and diseases relevant to the tumor angiogenesis and also can be used for treatment in tumor chemotherapy and / or auxiliary chemotherapy. In the application, the medicinal curative effect and effect mechanism of the active ingredients of juncus effuses are studied and clarified by taking tumor stem cells, tumor cells and tumor neoangiogenesis as targetspots for treating diseases so as to establish a foundation for the research and development of the active ingredients of juncus effuses and the innovative anti-tumor traditional Chinese medicines ofthe active ingredients and provide scientific basis and important information for the Chinese medicinal treatment of the malignancy.

Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.

The present invention involves the use of nitrone free radical trapping agents in the treatment and prevention of gliomas. The agents may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.

The invention relates to a breast cancer recurrent risk assessment 21 gene detection primer and application thereof. The breast cancer recurrent risk assessment 21 gene detection primer comprises a nucleotide sequence as shown in an SEQ ID NO.: 1 to 42, and belongs to the technical field of molecular detection. The detection primer provided by the invention utilizes the advantage of fluorescent quantitation, and adopts fluorescent quantitation polymerase chain reaction to carry out amplification detection on 21 genes for breast cancer recurrent risk assessment, so that whether clinical measurements such as adjuvant chemotherapy are needed or not is considered. A kit provides a PCR (Polymerase Chain Reaction) amplification primer sequence of the 21 genes for breast cancer recurrent risk assessment, and the primer is applicable to detecting ER positive patients, HER2 negative patients, axillary node negative patients, moderately and poorly differentiated patients with the tumor size being 0.6 to 1.0cm and adverse prognostic factors, or patients with the tumor size is larger than 1cm, has the advantages of high sensitivity and specificity, stability, promptness, convenience in operation and the like, can well meet the clinical application of breast cancer recurrent risk assessment, and can be beneficial for reducing invalid medication administration, improving medication administration accuracy, and reducing financial burdens of the patients.

The invention provides a system for predicting prognosis of gastric cancer of subjects. The system comprises: a data acquisition module, which is used for acquiring clinical characteristic data of thesubjects, immune marker characteristic data of the subjects and protein expression data of the subjects; a data processing module, which is used for further processing the data acquired in the data acquisition module; and a module for calculating the prognosis risk of the gastric cancer of the subjects, wherein the module utilizes the data processed in the data processing module to calculate theprognosis risk values of the gastric cancer of the subjects, and groups the subjects based on the risk values. According to the system and a method provided by the invention, eight characteristics, including five immunomarkers (CD3, CD4, PDL1, PAX5, and GZMB), an EMT protein marker (CDH1) and two clinical characteristics (pTNM and age), are selected to develop the system and the method that can significantly improve prognostic ability of gastric cancer patients. The system and the method may be applicable to patients with or without neoadjuvant chemotherapy and exhibit predicted values, and the patients may benefit from post-operative adjuvant chemotherapy.

The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.

The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC / EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC / CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC / 5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≧0.80 and the 5p15 / CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC / 5p15 ratio of <0.80 or 5p15 / CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.

The invention discloses a composition of albiziz durazz extract for inhibiting angiogenesis and preparation and application, belonging to the field of tradition Chinese medicine applied technique. The invention relates to a composition containing albiziz durazz extract, process for preparation and new usage. The invention discovers for the first time that the composition containing albiziz durazz extract can inhibit angiogenesis activity, and thereby the invention can be used for curing and preventing diseases relating to angiogenesis and also can be used for treatment of tumor chemotherapy and / or auxiliary chemotherapy. The composition of albiziz durazz extract of the invention contains one or a plurality of anti-angiogenesis active components. The invention skillfully takes angiogenesis as the target for curing diseases, studies and expounds medicinal curative effect and mechanism of composition containing albiziz durazz extract. The composition containing albiziz durazz extract can be used as drugs, health care products and / or cosmetics and the like.

The invention provides application of an emodin anthraquinone derivative in preparation of anti-hepatocellular carcinoma drugs. The emodin anthraquinone derivative is a 1, 4-dimethyl-6, 8-dimethoxy-9, 10-anthraquinone. The derivative not only can well inhibit proliferation of hepatocellular carcinoma cells, induce their apoptosis, and also has very small toxicity to normal cells. The derivative can be used in conjunction with 5-FU, cis-platinum and other chemotherapy drugs to increase the sensitivity of the chemotherapy drugs, thus achieving the effect of inhibiting hepatocellular carcinoma cell growth. Therefore, the emodin anthraquinone derivative can be used for preparing anti-hepatocellular carcinoma drugs or adjuvant chemotherapy drugs.

Disclosed is a method for survival prediction in gastric cancer patents after surgical operation, which uses a survival prediction model determined by known statistical method and gene expression microarray profiles. The survival prediction model is established by selecting special genes expressing significantly differential from pairs of cancerous and noncancerous tissue samples from patients with known survival conditions after surgical operation, confirming the concordance of RT-PCR analysis with the microarray gene expression profile, identifying most specific genes among the special genes using a statistical method, and determining the survival prediction model based on training set samples. The method of the present invention can be applied in gastric cancer patients to predict survival conditions after surgical operation and to provide a strategy for succeeding treatment and a reference for adjuvant chemotherapy.

The invention discloses a medicine composition for assisting chemotherapeutics and an application of the medicine composition. An effective dose of antrodia camphorata sporocarp extract is obtained by hot water soaking, low polar solvent extraction and other steps and collocated with a pharmaceutically acceptable supporting agent to prepare the medicine composition; the medicine composition can be used for improving a treatment effect of the chemotherapeutics cisplatin and gemcitabine on a cancer; and at the same time, the medicine composition can improve side effects such as hair slipping, muscle degradation and atrophy, gastrointestinal injury and kidney inflammation injury in a process of treating the cancer.

Application of ginsenoside IH901 in preparing angiogenesis inhibitors relates to the application of the ginsenoside IH901 in the medicament field. The invention provides application of ginsenoside IH901 and a precursor thereof in preparing angiogenesis inhibitors. The ginsenoside IH901 is 20-O-beta-D-glucopyranoside-20(S)-protopanoxadiol which can be used for preparing the angiogenesis inhibitors, and the precursor of the ginsenoside IH901 can be used for preparing the angiogenesis inhibitors. The extracted ginsenoside IH901 and the precursor have inhibitory effect on infiltration metastasis and angiogenesis and are used for preparing medicaments for treating diseases related to tumor angiogenesis and other angiogenesis. The ginsenoside IH901 and precursor are prepared into anti-tumor drugs and other drugs for angiogenesis, thus providing a research base for pharmacodynamics and action mechanism and having values of developing the ginsenoside IH901 and the precursor into drugs for tumor chemotherapy and / or auxiliary chemotherapy.

The invention provides a breast cancer prognosis evaluation model and an establishing method thereof. Differentially expressed genes are screened by selecting Chinese population as the research objectand through an RNA-seq method, the genes closely related to recurrence are screened out, and thus the prediction model suitable for the breast cancer recurrence risk of the Chinese population is obtained; and the model comprises the 190 genes which are differentially expressed in recurrence groups and non-recurrence groups and shown in the tablet 1. The model can provide more accurate individualized treatment effect prediction and ten-year recurrence risk prediction for early-stage breast cancer patients of the Chinese population, thus disease progression does not quickly occur in the high-risk population due to the lack of postoperative adjuvant chemotherapy, and the bodies of the low-risk population do not bear unnecessary chemotherapy toxic and side effects due to overtreatment either.

The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and / or diagnosing breast cancer, the metabolic biomarker set comprising at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Further, the invention relates to a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity. Further, the invention relates to a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, the present invention relates to a method for assessing breast cancer, which comprises obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and / or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.

The invention discloses a system for predicting prognosis of patients with lung adenocarcinoma and judging benefit of an adjuvant chemotherapy. The system comprises a system used for detecting expression quantities of six proteins, i.e., c-Src, Cyclin E1, TTF1, p65, CHK1 and JNK1, and a protein expression quantity data processing system. The system used for detecting the expression quantities of the six proteins can determine the expression quantities of the proteins by using an immunohistochemistry staining method; the protein expression quantity data processing system converts the expression quantities of the six proteins in lung adenocarcinoma tissues, separated from to-be-predicted patients with the lung adenocarcinoma, into a prognosis score, and predicting the prognosis of the to-be-predicted patients with the lung adenocarcinoma according to the prognosis score, and / or predicting whether the to-be-predicted patients with the lung adenocarcinoma are benefited from the adjuvant chemotherapy or not according to the prognosis score.

The invention provides a method for treatment of gastric cancer, which method is a postoperative adjuvant chemotherapy for gastric cancer, comprising orally administering, to a patient with gastric cancer in stage II, IIIA, or IIIB in a classification of the stage of gastric cancer, a pharmaceutical composition containing Tegafur, Gimeracil, and Oteracil potassium at a molar ratio of 1:0.4:1, at a dose of 50 to 150 mg / day as Tegafur dose and according to an administration schedule including, from within 45 days after a surgical operation of gastric cancer, drug administration for 28 consecutive days, followed by a rest period of 7 to 14 consecutive days.The chemotherapy reduces the relapse rate after a surgical operation, thereby improving the survival rate.

A method for predicting sensitivity of a cervical cancer patient subjected to paclitaxel and cis-platinum adopted chemotherapy comprises the steps: S1, preopreative examination is performed; S2, nidus analysis is performed; S3, mathematical statistics is performed; S4 sensitivity judgment is performed, namely serum SCC-Ag level analysis and post-chemotherapy MRI measurement are performed to judge chemotherapy sensitivity so as to determine whether a drug resistance rule is subjected to a postoperative pathological measurement result or not, it is confirmed that the patient is drug-sensitive if the drug resistance rule is subjected to the postoperative pathological measurement result, and it is confirmed that the patient is drug-resistant if the drug resistance rule is not subjected to the postoperative pathological measurement result. An experimental result of drug resistance analysis performed by means of the method for predicting the sensitivity of the cervical cancer patient subjected to the paclitaxel and cis-platinum adopted chemotherapy shows that change of the serum SCC-Ag level has close relationship with the sensitivity of cervical squamous cell neoadjuvant chemotherapy, important information can be provided for judgment on drug resistance of the patient, SCC-Ag and magnetic resonance imaging can be jointly and clinically utilized to assess the chemotherapy sensitivity, and the prediction accuracy is obviously higher than the prediction accuracy of an MRI imageology method widely and clinically used at present.

The invention discloses an application of vanillin in preparation of a nicotinamide-N-methyltransferase inhibitor. The inhibitor is prepared from traditional Chinese medicine monomer vanillin and pharmaceutically acceptable auxiliary materials. According to the invention, proliferation of various colorectal cancer cell strains is inhibited by inhibiting the expression of NNMT and enzyme activity in vitro and vivo, and an anti-tumor effect is achieved. Studies show that vanillin can weaken the drug resistance of colorectal cancer cell strains to 5-FU caused by high expression of NNMT in vitro,so that the chemotherapy sensitivity is enhanced; the apoptosis of the colorectal cancer cell strains with high expression of NNMT is increased by inducing ROS production and mitochondrial damage in cells; and the inhibitory effect of 5-fluorouracil on tumor proliferation and the apoptosis rate can be improved, so as to enhance the chemotherapy effect. The vanillin can be used as an NNMT inhibitorfor preparing anti-colorectal cancer drugs or adjuvant chemotherapy drugs, and has a good application prospect.

The invention provides application of polysaccharide sulphate to preparation of tumor treatment neovascularization inhibitors and vascular disrupting agents. Experiments prove that the neovascularization inhibiting rate, the maturation blood vessel disrupting rate and the concentration of the polysaccharide sulphate are in dosage relying relationship in a certain range, and the maturation blood vessel disrupting rate and the polysaccharide sulphate acting time are in dosage relying relationship. The application provided by the invention has the advantages that the effect of the polysaccharide sulphate in the aspects of tumor neovascularization inhibiting and tumor blood vessel generation disrupting can be proved, and the polysaccharide sulphate can be used for tumor blood vessel generation and other blood vessel generation disease treatment, and can also be used in aspects of tumor chemotherapy and / or auxiliary chemotherapy. Many diseases of people are relevant to the blood vessel generation, and the polysaccharide sulphate as the neovascularization inhibitors and vascular disrupting agents can be widely applied to the treatment of diseases of tumor and the like. The application provided by the invention has the advantages that the application range of the polysaccharide sulphate is widened, and the scientific basis is provided for the purpose development of the polysaccharide sulphate in the anti-tumor aspect and the like.

The invention relates to a preparation method and application of a low-toxicity effective fraction for suppressing angiogenesis in cowherb seed. The preparation method comprises the following steps of: heating and extracting cowherb seed with 75 percent of ethanol; and extracting the extract with petroleum ether, dichloromethane, ethyl acetate and water-saturated normal butanol in turn so as to obtain the effective fraction for suppressing angiogenesis in cowherb seed. Angiogenesis is taken as a target spot for treating a disease, and the medicinal curative effect and mechanism of the effective fraction in cowherb seed are searched and explained, so that scientific basis and important information are provided for the development of new application and finding of a new target spot with a medicinal effect. The effective fraction can be mixed with a pharmaceutically-applicable carrier so as to prepare various preparations. The effective fraction can be used for treating or preventing diseases related to angiogenesis and can be applied to treatment such as tumor chemotherapy and / or adjuvant chemotherapy.

The invention discloses a biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy. The biological marker is miR4772-3p. It is confirmed by experiments that: the miR-4772-3P expression level in blood exosome of curative effect SD group breast cancer patients is increased obviously compared with that of curative effect PR group breast cancer patients, so that miR4772-3p can be taken as the biological marker used for prediction of responsiveness of breast cancer patients on AT programme neoadjuvant chemotherapy. The research results can be used for providing guidance for development of therapeutic schedules of breast cancer patients by clinical doctors.

The invention discloses application of Juncus effuses L. extract in preparing an anti-tumor or angiogenesis-inhibiting medicament. The invention discloses that the Juncus effuses L. extract has activities of inhibiting tumor and tumor angiogenesis for the first time, and the Juncus effuses L. extract can be used for treating or preventing diseases related to tumor and tumor angiogenesis, and also can be used in treatment for chemotherapy and / or adjuvant chemotherapy of tumor. The invention takes angiogenesis as the target spot for treating diseases, studies and explains the pharmaceutical curative effects and mechanism of the Juncus effuses L. extract, and provides a scientific basis and important information for the development of new use of the Juncus effuses L. extract and discovery of new target spots of drug action. The Juncus effuses L. extract can be applied to medicaments, health products and / or cosmetics and the like.

The invention belongs to the field of pharmaceutical preparations, and relates to a tumor targeted drug nanocrystal delivery system and a preparation method and application thereof in pharmacy. The tumor targeted drug nanocrystal delivery system is composed of an anti-tumor drug nanocrystal core and a coating material; one or more biocompatible phospholipids, vitamin E polyethylene glycol 1000 succinate, folic acid-polyethylene glycol-phosphatidyl ethanolamine and methoxy polyethylene glycol-phosphatidyl ethanolamine are mixed according to a certain ratio, and insoluble anti-tumor drug nanocrystals are coated with the obtained mixture; the obtained tumor targeted drug nanocrystal drug delivery system can be stably dispersed in an aqueous environment, and experiments prove that the tumor targeted drug nanocrystal drug delivery system can effectively inhibit the growth of tumor cells and can effectively reduce the tumor volume after being subjected to peritumoral injection for an animalmodel. The invention provides a new preparation form capable of peritumoral injection for preoperative adjuvant chemotherapy of a solid tumor.

The invention discloses an application of a reagent for detecting gene expression level and a construction method of an NAC (neoadjuvant chemotherapy) curative effect prediction model for breast cancer patients, and relates to the technical field of breast cancer. Particularly, the prediction model can predict the curative effect of anthracyclines and taxus drugs in NAC, so as to provide a basis for whether the breast cancer patients accept NAC regimens or choose which type of NAC regimens. The patients who are sensitive to chemotherapy regimens and may reach pCR can seize the opportunity of NAC by predicting the curative effect, so that effective NAC is conducted, and the breast-conserving rate or survival rate is increased; however, the patients who are insensitive to chemotherapy regimens or may cause tumor progression can choose other effective treatments in time.

The invention discloses the application of erigeron breviscapus extract in preparing anti-tumor or angiogenesis-suppressing medicine, health-care food or cosmetics. It is the first revelation that the erigeron breviscapus extract has the activities of suppressing tumor and angiogenesis, can treat or prevent the diseases relative to the tumor and the angiogenesis and can be applied to the tumor chemotherapy and / or auxiliary chemotherapy. The angiogenesis as the target point of treating the diseases is used skillfully, and the medicinal effectiveness and the mechanism of the erigeron breviscapus are studied and clarified, so that the invention provides the scientific evidence and the important information for the new target points of developing new uses and discovering drug action and is the new theory development of traditional Chinese medicine. The erigeron breviscapus extract can be applied to the medicaments, health-care products and / or cosmetics.

The invention relates to an SNP marker associated with a curative effect of novel adjuvant chemotherapy of a breast cancer and an application of the SNP marker, and particularly relates to an SNP marker associated with the curative effect of novel adjuvant taxol chemotherapy of the breast cancer and an application of the SNP marker. The SNP marker comprises an rs2981578 site on an FGFR2 gene and an rs1966265 site on an FGFR4 gene. The application is the application as the SNP marker. The invention further provides a kit for detecting or predicting the curative effect of novel adjuvant chemotherapy of the breast cancer. The SNP marker can be applied to detection or prediction of the curative effect of the novel adjuvant taxol chemotherapy of the breast cancer, a basis is provided for implementation of individualized treatment of a patient, and the SNP marker is used for guiding individualized treatment, improving prognosis of the patient and improving the effectiveness and the security of clinical medication.

The invention discloses a biomarker for forecasting the new auxiliary chemotherapy curative effect of breast cancer and a fluorescence quantitative immune PCR kit. The biomarker is at least one of a CCL2 gene, a CCR1 gene, a CXCL10 gene, a CXCL11 gene and an IL2RG gene. The five genes of the biomarker are efficiently expressed in a pCR group; the IL2RG gene has an extremely obvious expression difference (P is less than 0.01) in the pCR group and the NpCR group, and the other four genes have an obvious expression difference (P is less than 0.05) in the pCR group and the NpCR group; the five genes are indicated to be biomarkers for forecasting the new auxiliary chemotherapy curative effect of the breast cancer, and the blindness of new auxiliary chemotherapy is avoided.

The invention belongs to the technical field of traditional Chinese medics and traditional Chinese medicine, and in particular relates to a traditional Chinese medicine composition for alleviating side effects of chemotherapy. The traditional Chinese medicine composition is made from the following materials in parts by weight: 3-5 parts of ginseng flower, 8-15 parts of angelica sinensis, 3-5 parts of poria cocos, 3-5 parts of astragalus membranaceus, 3-5 parts of saffron crocus, 3-5 parts of medlar, 3-5 parts of polygonum multiflorum, 3-5 parts of sealwort, 1-3 parts of fructus psoraleae, 1-3 parts of radix paeoniae alba, 1-3 parts of oldenlandia diffusa, 1-3 parts of semen coicis, 1-2 parts of fiveleaf akebia fruit, 3-5 parts of dendrobe, 2-3 parts of radix ophiopogonis, 1-2 parts of fructus amomi, 3-5 parts of endothelium corneum gigeriae galli and 1-3 parts of liquorice. The preparation method is to decoct by water; through the effect of the traditional Chinese medicine on tonifying deficiency and qi, enriching blood and replenishing essence, tonifying spleen and appetizing and enhancing immunity, the traditional Chinese medicine composition eliminates adverse effects caused by chemotherapy, assists chemotherapeutics to exert therapeutic action, is gentle in nourishing, relieves body burden of a patient, and quickens recovery of the human body.

The present invention discloses an application of dehydroeffusol (the chemical name is 2,7-dihydroxy-1-methyl-5-vinylphenanthrene, the molecular formula is C17H14O2, and the molecular weight is 250) in preparation of drugs for tumor preventing and tumor angiogenesis inhibiting, or health food or cosmetics. According to the present invention, the results firstly show that: the Chinese herbal medicine monomer dehydroeffusol has activities of tumor inhibiting and tumor angiogenesis inhibiting, such that the prepared drug for tumor inhibiting and tumor angiogenesis inhibiting by the results can be used for treatments or preventions of diseases related to malignant tumors and tumor angiogenesis, and further can be used for treatments in the fields of tumor chemotherapy and / or adjuvant chemotherapy. According to the present invention, tumor stem cells, tumor cells and tumor angiogenesis are masterly adopted as the targets, and the medicinal efficacy and the action mechanism of the dehydroeffusol are studied and represented, such that the foundation is established for development of innovative anti-tumor traditional Chinese drug of the dehydroeffusol, and the scientific basis and the important information are provided for treatment of the malignant tumors by the traditional Chinese drug.